NIH initiated clinical trials to test IL-23 antibodies;

According to the World Health Organization, more than 38.3 million people worldwide have been infected with the new coronavirus, as more than 1 million people have died from COVID-19.
recently, the number of newly diagnosed patients in many countries and regions has increased again, with the advent of autumn and winter in the northern hemisphere, the expansion of the COVID-19 epidemic in the world is still facing serious challenges.
challenges of the COVID-19 outbreak have also inspired unprecedented investment and efforts by the pharmaceutical industry in the development of treatments and vaccines.
more than 400 treatments for COVID-19 are currently in clinical trials, and more than 40 new crown-candidate vaccines are in clinical development, according to BioCentury.
researchers are constantly exploring new treatments and prevention methods, and here are the latest advances in COVID-19 research and development.
Pharmaceuticals Mingkangde Content Team Map NIH initiated Adaptive Phase 2 clinical trials to explore potential coVID-19 therapies A few days ago, the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced the launch of an Adaptation Phase 2 clinical trial aimed at more effectively exploring the efficacy of approved or in-study therapies for COVID-19 and finding candidate therapies suitable for testing in larger clinical trials.
clinical trial, called ACTIV-5/BET, will register hospitalized COVID-19 patients at nearly 40 trial points in the United States.
the trial was designed as an adaptive, randomized double-blind, placebo-containing controlled trial that compared a variety of different in-study therapies with the same control group, each of which enrolled about 100 hospitalized participants.
the clinical trial will initially test the effectiveness of the IL-23 antibody Risankizumab (commodity name Skyrizi) developed jointly by Boehringer Ingelheim and AbbVie to treat hospitalized COVID-19 patients compared to placebo and redsiwe.
has been shown to be effective in Phase 3 clinical trials as part of a standard treatment.
Skyrizi has been approved by the FDA to treat psoriasis, which inhibits the IL-23 signaling pathrapies and plays an important role in mediaing a variety of inflammatory diseases.
in addition to controlling the proliferation of viruses, inhibiting excessive inflammatory response from cytokine storms in COVID-19 patients is also an important direction for the development of therapy.
, Lilly and Incyte jointly developed the JAK inhibitor baricitinib in a clinical trial called ACTT-2 to reduce patient mortality.
another in-study therapy developed for Humanigen.
Lenzilumab is a granulocyte macrophage collection stimulation factor (GM-CSF) that nucleates and antibodies.
it has the potential to prevent or reduce serious side effects associated with CAR-T therapy, as well as to treat graft anti-host disease (GvHD) by inhibiting GM-CSF activity.
Humanigen has been working with the Mayo Clinic and Dartmouth Medical School to conduct Phase 3 clinical trials to test the effectiveness of the therapy in preventing and treating cytokine storms and excessive inflammation in patients with COVID-19.
in ACTIV-5/BET, lenzilumab will also be used in combination with Redsiway to treat COVID-19 inpatients.
"The goal of this trial is to find promising COVID-19 therapies as soon as possible so that they can be evaluated in large-scale clinical trials," said Dr. Anthony S. Fauci, DIRECTOR of NIAID.
" Xenofi/Translate Bio New Crown Candidate Vaccine Obtains Positive Preclinical Results Sanofi's Global Vaccine Development Division Sanofi Pasteur and Translate Bio today announced that the mRNA New Crown Candidate Vaccine MRT5500, developed jointly, has achieved positive results in preclinical animal trials, with strong responses in both mouse and monkey models.
results of this study were published today on the preprinted website bioRxiv.
in the monkey model, after two doses of the candidate vaccine 21 days apart, levels of new coronavirus and antibodies in animals increased significantly and peaked 35 days after the first dose of the vaccine.
Using both detection methods of false virus and detection and detection of live neo-coronavirus, the moderate antibody titration excited by MRT5500 at doses of 45 μg and 135 μg significantly exceeded the average moderate antibody titration in the serum of rehab COVID-19 patients. both
-counterfeit virus and detection (left) and live neo-coronavirus (right) showed that MRT5500 excites a strong antibody immune response (vaccination occurs on day 0 and day 21, photo source: Reference 3)) researchers also tested the T-cell immune response stimulated by the new coronavirus.
Tests of T-cytokine responses in monkey models showed that on the 42nd day after the first vaccination, most animals had cells that secreted IFN-γ, a cytokine associated with γ TH1 immune response.
same time, tests did not find cells secreting IL-13 cytokines (associated with the TH2 immune response).
results show that vaccination mainly stimulates tY-cell immune responses that tend to be TH1, which will help animals produce long-term immune responses.
based on these positive results, Sanofi Pasteur and Translate Bio plan to launch Phase 1/2 clinical trials in the fourth quarter of this year, in favor of secretion of IFN-γ rather than IL-13 (Photo Source: Reuters)